Pharmaceutical

Dren Bio and Novartis link on bispecific antibodies for cancer

Dren Bio has entered a strategic partnership with Novartis Pharma to develop therapeutic bispecific antibodies to treat cancer.

Jul 26, 2024 - 04:00
Dren Bio and Novartis link on bispecific antibodies for cancer
Dren Bio has entered a strategic partnership with Novartis Pharma to develop therapeutic bispecific antibodies to treat cancer.
Read the original article

Tags:

Previous Article

NICE recommends Boehringer’s tenecteplase for NHS stroke care

Next Article

MHRA approves Pfizer-BioNTech’s Comirnaty JN.1 vaccine

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstraZeneca mulls risk strategy for Ultomiris following FDA response letter

AstraZeneca mulls risk strategy for Ultomiris following...

Sep 7, 2023

Why do some women experience UTI pain with no clear infection? A mouse study offers clues

Why do some women experience UTI pain with no clear inf...

Mar 2, 2024

FDA approves AstraZeneca, Ionis treatment for rare nerve disease

FDA approves AstraZeneca, Ionis treatment for rare nerv...

Dec 21, 2023